MJL Manager LLC has reported an increase in its beneficial ownership of Soligenix, Inc., now holding 2,053,706 shares, which constitutes 9.4% of the company’s common stock. This update comes through a Schedule 13G/A filing made on November 2, 2026, indicating MJL's ongoing investment strategy in the pharmaceutical preparations sector.

Soligenix, Inc. is a biopharmaceutical company focused on developing products to treat rare diseases and conditions. The company is incorporated in Delaware and operates out of Princeton, New Jersey. This filing marks a significant moment for MJL Manager LLC, which is the general partner of Capuchin Capital Fund LP, as it continues to expand its influence in the life sciences industry.

The filing specifies that MJL Manager LLC holds no sole voting power over the shares but has shared voting and dispositive power over the 2,053,706 shares. Michael Liu, the sole control person of MJL, also holds the same number of shares, asserting his authority to direct the voting and disposition of these shares.

"MJL Manager LLC is the general partner of Capuchin Capital Fund LP," the filing states, highlighting the structured nature of its investment strategy.

This increase in ownership may have implications for Soligenix, Inc., particularly as MJL Manager LLC could influence corporate governance decisions. The pharmaceutical preparations industry is known for its volatility, and significant stakeholders often play a crucial role in shaping company strategies and directions.

As for what’s next, the filing does not specify any upcoming actions or votes related to this ownership increase. However, it does indicate MJL Manager LLC's commitment to its investment in Soligenix, Inc.